Resumen
Introducción: el uso de los análogos del receptor del GLP-1 (arGLP-1) como terapia para la obesidad y la diabetes tiene una tendencia acelerada. Su utilización ha ocurrido sin que se conozca de manera integral el espectro completo de sus posibles reacciones adversas inusuales.
Objetivo: realizar una búsqueda estructurada de la literatura y describir las reacciones adversas poco frecuentes asociadas a los arGLP-1.
Metodología: se realizó una exploración de la literatura entre enero y noviembre de 2026, con búsquedas complementarias durante la elaboración del manuscrito para incorporar la evidencia reciente. No se establecieron restricciones por año de publicación dada la pertinencia de incluir estudios base para el entendimiento de los mecanismos fisiopatológicos, así como investigaciones recientes. La selección de las publicaciones se orientó a dar respuesta a la pregunta: ¿cuáles son las reacciones adversas poco comunes asociadas al uso de arGLP-1 y cuál es su relevancia clínica? La búsqueda se hizo a través de los descriptores MeSH: “Glucagon-Like Peptide 1 Receptor Agonists” y “Drug-Related Side Effects and Adverse Reactions”, combinados con términos relacionados con la frecuencia (‘Rare’, ‘Uncommon’) y la relevancia clínica (‘Treatment outcome’, ‘Risk Assessment’), así como con términos libres relacionados con los fármacos específicos (semaglutide, liraglutide y tirzepatide) y sus posibles efectos adversos, incluyendo ‘hair loss’, ‘alopecia’, ‘telogen effluvium’, ‘facial volume loss’ y ‘Ozempic face’, en las bases de datos PubMed® y Scopus.
Resultados: la mayoría de las reacciones adversas evaluadas por los sistemas fueron inusuales. A pesar de esto, no debe dejarse de lado la importancia del seguimiento estrecho con estas moléculas, ya que no es un fármaco exento de complicaciones y el receptor GLP-1 se expresa en múltiples órganos.
Conclusiones: el profesional de la salud debe tomar decisiones individualizadas conociendo el espectro completo de los posibles efectos de estos fármacos en tendencia.
Citas
Cruz-Rojas JD, Jiménez-Canizales CE, Bahamón-Rivera H. Perspectivas en el manejo de la obesidad según la evidencia actual. Acta Méd Col. 2025; 50(3 Supl). https://doi.org/10.36104/amc.2025.4884
Christensen RM, Juhl CR, Torekov SS. Benefit-risk assessment of obesity drugs: Focus on glucagon-like peptide-1 receptor agonists. Drug Saf. 2019; 42: 957-71. https://doi.org/10.1007/s40264-019-00812-7
He L, Wang J, Ping F, Yang N, Huang J, Li Y, et al. Association of glucagon-like peptide-1 receptor agonist use with risk of gallbladder and biliary diseases: A systematic review and meta-analysis of randomized clinical trials. JAMA Intern Med. 2022; 182(5): 513-519. https://doi.org/10.1001/jamainternmed.2022.0338
Ionut Feier CV, Vonica RC, Faur AM, Streinu DR, Muntean C. Assessment of thyroid carcinogenic risk and safety profile of GLP1-RA semaglutide (ozempic) therapy for diabetes mellitus and obesity: A systematic literature review. Int J Mol Sci. 2024; 25(8), 4346. https://doi.org/10.3390/ijms25084346
Liu Y, He L, Han S, Ping F, Li W, Xu L, et al. Glucagon-like peptide-1 receptor agonists and risk of venous thromboembolism: A systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc. 2025; 14(9): e039446. https://doi.org/10.1161/JAHA.124.039446
Tang H, Lu Y, Donahoo WT, Westen SC, Chen Y, Bian J, et al. Glucagon-like peptide-1 receptor agonists and risk for depression in older adults with type 2 diabetes: A target trial emulation study. Ann Intern Med. 2025; 178(3): 315-326. https://doi.org/10.7326/ANNALS-24-01347
Taipale H, Taylor M, Lähteenvuo M, Mittendorfer-Rutz E, Tanskanen A, Tiihonen J. Association between GLP-1 receptor agonist use and worsening mental illness in people with depression and anxiety in Sweden: A national cohort study. Lancet Psychiatry. 2026; 13(4): 327-335. https://doi.org/10.1016/S2215-0366(26)00014-3
Lakhani M, Kwan ATH, Mihalache A, Popovic MM, Nanji K, Xie JS, et al. Association of glucagon-like peptide-1 receptor agonists with optic nerve and retinal adverse events: A population-based observational study across 180 countries. Am J Ophthalmol. 2025; 277: 148-168. https://doi.org/10.1016/j.ajo.2025.05.007
Liu L, Mohan S, Wu L. GLP-1 receptor agonists and non-arteritic anterior ischemic optic neuropathy: What an endocrinologist needs to know. J Clin Endocrinol Metab. 2026; 111(1): e308-e313. https://doi.org/10.1210/clinem/dgaf541
Hu W, Song R, Cheng R, Liu C, Guo R, Tang W, et al. Use of GLP-1 receptor agonists and occurrence of thyroid disorders: A meta-analysis of randomized controlled trials. Front Endocrinol. 2022; 13: 927859. https://doi.org/10.3389/fendo.2022.927859
Morales DR, Bu F, Viernes B, DuVall SL, Matheny ME, Simon KR, et al. Risk of thyroid tumors with GLP-1 receptor agonists: A retrospective cohort study. Diabetes Care. 2025; 48(8): 1386-1394. https://doi.org/10.2337/dc25-0154
Gallagher TJ, Razura DE, Li A, Kim I, Vukkadala N, Barbu AM. Glucagon-like peptide-1 receptor agonists and chronic cough. JAMA Otolaryngol Head Neck Surg. 2026; 152(2): 163-171. https://doi.org/10.1001/jamaoto.2025.4181
Sun Y, Liu Y, Dian Y, Zeng F, Deng G, Lei S. Association of glucagon-like peptide-1 receptor agonists with risk of cancers-evidence from a drug target Mendelian randomization and clinical trials. Int J Surg. 2024; 110(8): 4688-4694. https://doi.org/10.1097/JS9.0000000000001514
Lu Y, Dai H, Tang H, Donahoo WT, George TJ, Sun RC, et al. Association of glucagon-like peptide-1 receptor agonists with cancer risk in older adults with type 2 diabetes. Obesity. 2025; 34(52): 75-87. https://doi.org/10.1002/oby.24366
Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015; 373: 11-22. https://doi.org/10.1056/NEJMoa1411892
Davies MJ, Bergenstal R, Bode B, Kushner RF, Lewin A, Skjøth TV, et al. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: The Scale diabetes randomized clinical trial. JAMA. 2015; 314(7): 687-699. https://doi.org/10.1001/jama.2015.9676
Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016; 375(19): 1834-1844. https://doi.org/10.1056/NEJMoa1607141
Alfakhri A, Almadani O, Alroba R, Alrwisan A, Alshaya O, Albogami Y. The risk of hypothyroidism with the use of GLP-1 receptor agonists in Saudi Arabia. Pharmacoepidemiol Drug Saf. 2026; 35(1): e70315. https://doi.org/10.1002/pds.70315
Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (Rewind): A double-blind, randomised placebo-controlled trial. Lancet. 2019; 394(10193): 121-30. https://doi.org/10.1016/S0140-6736(19)31149-3
Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016; 375: 311-322. https://doi.org/10.1056/NEJMoa1603827
Pasternak B, Wintzell V, Hviid A, Eliasson B, Gudbjörnsdottir S, Jonasson C, et al. Glucagon-like peptide 1 receptor agonist use and risk of thyroid cancer: Scandinavian cohort study. BMJ. 2024; 385: e078225. https://doi.org/10.1136/bmj-2023-078225
Yin DG, Ding LL, Zhou HR, Qiu M, Duan XY. Comprehensive analysis of the safety of semaglutide in type 2 diabetes: A meta-analysis of the Sustain and Pioneer trials. Endocr J. 2021; 68(6): 739-742. https://doi.org/10.1507/endocrj.EJ21-0129
Rosen CJ, Ingelfinger JR. GLP-1 receptor agonists. N Engl J Med. 2026; 394(13): 1313-1324. https://doi.org/10.1056/NEJMra2500106
Davies M, Færch L, Jeppesen OK, Pakseresht A, Pedersen SD, Perreault L, et al. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (Step 2): A randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021; 397(10278): 971-984. https://doi.org/10.1016/S0140-6736(21)00213-0
Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017; 377(13): 1228-1239. https://doi.org/10.1056/NEJMoa1612917
Weinstock RS, Guerci B, Umpierrez G, Nauck MA, Skrivanek Z, Milicevic Z. Safety and efficacy of once-weekly dulaglutide versus sitagliptin after 2?years in metformin-treated patients with type 2 diabetes (Award-5): A randomized, phase III study. Diabetes Obes Metab. 2015; 17(9): 849-858. https://doi.org/10.1111/dom.12479
Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Køber LV, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015; 373(23): 2247-2257. https://doi.org/10.1056/NEJMoa1509225
Fathizadeh BS, Hwang MAS, Hoss ME. Ozempic face and facial aging. Clinics in Dermatology. Elsevier; 2026. https://doi.org/10.1016/j.clindermatol.2026.10.004
Seyed Jafari SM, Caro G, Lipner SR, Iorizzo M. The impact of GLP-1 receptor agonists on hair: Beneficial effects or adverse outcomes? Am J Clin Dermatol. 2026; 27: 579-586. https://doi.org/10.1007/s40257-026-01021-6
Jensen SBK, Sørensen V, Sandsdal RM, Lehmann EW, Lundgren JR, Juhl CR, et al. Bone health after exercise alone, GLP-1 receptor agonist treatment, or combination treatment: A secondary analysis of a randomized clinical trial. JAMA Netw Open. 2024; 7(6): e2416775. https://doi.org/10.1001/jamanetworkopen.2024.16775
Wharton S, Aronne LJ, Stefanski A, Alfaris NF, Ciudin A, Yokote K, et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment. N Engl J Med. 2025; 393(18): 1796-1806. https://doi.org/10.1056/NEJMoa2511774
Rubin R. Data on 3 new GLP-1 Drugs for weight loss that may be approved this year. JAMA. 2026; 335(8): 653-655. https://doi.org/10.1001/jama.2026.0287
Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022; 387(3): 205-216. https://doi.org/10.1056/NEJMoa2206038
Malhotra A, Grunstein RR, Fietze I, Weaver TE, Redline S, Azarbarzin A, et al. Tirzepatide for the treatment of obstructive sleep apnea and obesity. N Engl J Med. 2024; 391(13): 1193-1205. https://doi.org/10.1056/NEJMoa2404881
Newsome PN, Buchholtz K, Cusi K, Linder M, Okanoue T, Ratziu V, et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med. 2021; 384:1113-1124. https://doi.org/10.1056/NEJMoa2028395
Sanyal AJ, Newsome PN, Kliers I, Østergaard LH, Long MT, Kjær MS, et al. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. N Engl J Med. 2025; 392: 2089-2099. https://doi.org/10.1056/NEJMoa2413258
U.S. Food and Drug Administration. FDA requests removal of suicidal behavior and ideation warning from glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications. 2026 https://www.fda.gov/media/190557/download

Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.
Derechos de autor 2026 Revista Colombiana de Endocrinología, Diabetes & Metabolismo

